Blog
RSS FeedPosted by Michael Wonder on 23 Jun 2016
New guidance from NICE recommends Humira (adalimumab), the only licensed biologic for treatment of hidradenitis suppurativa, a debilitating and disfiguring skin condition
22 June 2016 - AbbVie today announced that the NICE has published single technology appraisal guidance for the only licensed ...
Posted by Michael Wonder on 23 Jun 2016
Agreement with Biotronik Australia for the supply of interventional cardiology devices
23 June 2016 - PHARMAC is pleased to announce the approval of an agreement with Biotronik Australia Pty Limited for the ...
Posted by Michael Wonder on 22 Jun 2016
CADTH calls for feedback on drugs for the management of rheumatoid arthritis
22 June 2016 - A list of included studies on drugs for the management of rheumatoid arthritis is now available for ...
Posted by Michael Wonder on 22 Jun 2016
NICE gives conditional backing for GSK’s Benlysta in lupus
22 June 2016 - NICE has today published final guidance which recommends UK pharma major GlaxoSmithKline’s Benlysta (belimumab) for treating systemic ...
Posted by Michael Wonder on 22 Jun 2016
UK drugs watchdog NICE approves five new treatments in coup for big pharma
22 June 2016 - The UK agency in charge of deciding which drugs the NHS will pay for has approved five ...
Posted by Michael Wonder on 21 Jun 2016
Removal of blood glucose test strips from the PBS on 1 July 2016
21 June 2016 - From 1 July 2016 blood glucose test strips will no longer be available on the PBS. ...
Posted by Michael Wonder on 21 Jun 2016
Agreement with Smith & Nephew for the supply of orthopaedic trauma implants
21 June 2016 - PHARMAC is pleased to announce the approval of an agreement with Smith and Nephew for the supply ...
Posted by Michael Wonder on 20 Jun 2016
Notification of outcomes for the 2016 October cycle of price disclosure
20 June 2016 - The Minister’s delegate will consider making the weighted average disclosed price determination for the 2016 October Cycle ...
Posted by Michael Wonder on 20 Jun 2016
Valuing the benefits of new anti-cancer drugs
20 June 2016 - Improvements in survival and cancer-related symptoms must be weighed up against treatment-related adverse effects and financial burden. ...
Posted by Michael Wonder on 19 Jun 2016
Cancer patients hurt by lack of informed choice on costs, options
20 June 2016 - Doctors who are not upfront with cancer patients about likely out-of-pocket costs and other options are causing ...
Posted by Michael Wonder on 18 Jun 2016
Political parties commit support for community pharmacy model
17 June 2016 - With 17 days until the Federal election, the pharmacy and broader health policies of the political parties ...
Posted by Michael Wonder on 18 Jun 2016
Drug combination for treating skin cancer approved for NHS use
17 June 2016 - Medicines regulator NICE moves at record speed to approve nivolumab for use with ipilimumab in melanoma patients. ...
Posted by Michael Wonder on 17 Jun 2016
Section 100 IVF Program - updated claiming arrangements
17 June 2016 - From 1 July 2016, approved suppliers will be required to submit a Reproductive Technology Accreditation Committee (RTAC) ...
Posted by Michael Wonder on 17 Jun 2016
Cost of cystic fibrosis treatment too high for benefit offered, says NICE
17 June 2016 - NICE has said it will not be able to recommend Orkambi (lumacaftor with ivacaftor, Vertex Pharmaceuticals) for ...
Posted by Michael Wonder on 16 Jun 2016
Sacubitril with valsartan in heart failure: differentiated value added
16 June 2016 - Addendum results in a revised benefit assessment for patients with type 2 diabetes mellitus. ...